Inhibitor development has long been considered the most significant complication of severe hemophilia, but with the licensure of the first non-factor therapy and a robust pipeline of novel and gene therapeutics being investigated, is it still of critical importance that we better understand inhibitors? If so, what research is currently taking place, and what can he hope to learn from it? This episode of the Global Hemophilia Report from BloodStream Media features contributions and citations from investigators, clinicians, and research funders dedicated to this topic, as well as from patients and caregivers who can speak to their lived experience of inhibitors.   For more on inhibitor research:

• Inhibitors and Hemophilia - CDC
• ATHN 8: PUPs Matter Study - ATHN
• The Hemophilia Inhibitor Eradication Trial - ClinicalTrials.gov
• A New Plan for Tackling Inhibitors - NHF
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders - ASH
• The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development - ASH

  Show Notes:

Featured Advertiser: Sanofi Genzyme

Subscribe to BloodStream Media’s Global Hemophilia Report

Senior Adviser: Dr. Donna DiMichele

 

Connect with the Global Hemophilia Report

Global Hemophilia Report on LinkedIn

Global Hemophilia Report on Twitter

Global Hemophilia Report on Facebook

 

Connect with BloodStream Media:

BloodStreamMedia.com

BloodStream on Facebook 

BloodStream on Twitter